Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to allegations of misleading statements regarding the company's prostate cancer therapeutic candidates and supply chain quality, which have resulted in significant stock price declines [2][4][5][6]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Telix between February 21, 2025, and August 28, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Telix, with a deadline of January 9, 2026, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [7]. Group 2: Allegations Against Telix - The complaint alleges that Telix and its executives violated federal securities laws by making false and misleading statements about the progress of their prostate cancer therapeutic candidates and the quality of their supply chain [4]. - Specific allegations include that Telix materially overstated its progress and the quality of its partnerships, leading to misleading statements about its business and operations [4]. - Following the announcement of a subpoena from the U.S. Securities and Exchange Commission, Telix's stock price fell over 13% in two trading sessions [5]. Group 3: Regulatory Challenges - On August 28, 2025, Telix disclosed receiving a Complete Response Letter from the FDA regarding its product TLX250-CDx, citing deficiencies in the Chemistry, Manufacturing, and Controls package [6]. - This disclosure led to a further decline of over 21% in Telix's stock price over two trading sessions [6].
SHAREHOLDER ALERT: Faruqi & Faruqi Reminds Telix Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026